Castle Biosciences, Inc. (CSTL)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
CSTL Chart
People also search for
Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
Castle Biosciences NASDAQ: CSTL reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its reported beat, according to CFO Frank Stokes.
Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript
Castle Biosciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 58 | $1,205.21 | $1,870.21 | $665 | 55.18% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 3,977 | $83,864.37 | $128,357.67 | $44,493.3 | 53.05% |
| NA Nizar Araji National Bank Of Canada /FI/ | 191 | $4,645.12 | $6,178.85 | $1,533.73 | 33.02% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 31,748 | $803,224.4 | $1.02M | $213,664.01 | 26.6% |
| BG Bart Gancher Intech Investment Management LLC | 8,580 | $208,665.6 | $277,563 | $68,897.4 | 33.02% |
Castle Biosciences, Inc. (CSTL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Castle Biosciences, Inc. ever had a stock split?
Castle Biosciences, Inc. Profile
| Professional Services Industry | Industrials Sector | Derek J. Maetzold CEO | NASDAQ (NMS) Exchange | 14843C105 CUSIP |
| US Country | 1,002 Employees | - Last Dividend | - Last Split | 25 Jul 2019 IPO Date |
Overview
Castle Biosciences, Inc. is a pioneering molecular diagnostics company that focuses primarily on devising testing solutions to aid in the diagnosis and effective treatment of various conditions, including dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health disorders. The company leverages its expertise in gene expression profiling and pharmacogenomics to develop tests that can significantly influence patient management decisions, particularly in the areas of skin cancer, gastroenterology, and mental health. Established in 2007, Castle Biosciences is headquartered in Friendswood, Texas, where it continues to innovate in the field of molecular diagnostics, emphasizing its commitment to improving patient outcomes by providing pivotal information that can guide treatment decisions.
Products and Services
- DecisionDx-Melanoma: This is a risk stratification gene expression profile (GEP) test designed to ascertain the metastasis risk in patients diagnosed with invasive cutaneous melanoma. The test aids in the identification of patients at high risk of metastasis, which can have significant implications for treatment planning and patient management.
- DecisionDx-SCC: A proprietary GEP test that serves as a risk stratification tool for patients with cutaneous squamous cell carcinoma. This test provides critical information regarding the likelihood of disease progression, assisting in the customization of patient care plans.
- MyPath Melanoma: Targeted at patients with melanocytic lesions that are hard to diagnose, MyPath Melanoma helps in delineating benign nevi from malignant melanoma, aiding clinicians in making informed decisions about patient management.
- TissueCypher: This spatial omics test is designed to predict the future development of high-grade dysplasia and/or esophageal cancer in patients with Barrett's esophagus, including those with non-dysplastic, indefinite for dysplasia, or low-grade dysplasia. The test plays a crucial role in early detection and prevention strategies.
- DecisionDx-UM: A proprietary risk stratification GEP test for patients with uveal melanoma, DecisionDx-UM predicts the risk of metastasis, guiding clinical management and surveillance strategies for patients diagnosed with this rare but aggressive form of melanoma.
- IDgenetix: This pharmacogenomic test is designed to assist in guiding drug treatment decisions for a range of mental health conditions, including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. By analyzing genetic variations that affect drug response, IDgenetix helps to personalize medication regimens for improved efficacy and reduced side effects.
